ATL1102 US Patent - very interesting, page-36

Speaking of the trials and PRV, cash at bank today is @$10m which is enough to get the EU trial to approval point but not enough to begin. EMA and FDA have a responsibility to ensure that any drug trial application also has the financial capability to complete the trial and process the data to conclusion. Right now, ANP don't have that. The EU trial alone will cost @$20m to complete so at some point, these funds must be raised. If they want to move into other Ph2 trials for other diseaases, then the kitty will need to be even bigger. The big question is how ?
The solutions while many and varied are anything from equity, debt, JV, partnerships, licensing deals for 1103 or even 1102 etc. But what's best for shareholders is the pivot point. Dilution provides cash to act quickly, but ultimately we may have to give away too much. $20m raise with the current MC @$90m could leave the wheels spinning for a lot longer. Grant funding would be helpful, but unlikely to cover all of the costs. Partnerships would help promote and elevate ANP to the table but pharma bullies can be dangerous.
Then there's the sale of the PRV. At what point can it be sold ? I can't actually recall, help please ?
And at what point should it be sold to leverage the highest value ?

Given this is the next big financial decision for ANP, it helps explain a depressed SP if equity is a possibility. If it turns out that equity is not the preferred solution then the price should react positively and quickly.
Lastly, I don't see ANP as a take-over target pre P2b trial results. This company really need to have a value 10x it's current price to even get on the radars of companies that are capable to aquire, progress, manufacuter and distribute drugs like 1102.

Thoughts please.